• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Gliknik

edit

Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves in off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the eficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to moncolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.

Recent Milestones

edit

• 
  Gliknik received $20M in Venture Round funding. (5/13/13)
  Posted 5/13/13 at 6:47pm via dowjones.com
• 
  Gliknik received $4.9M in Series B funding. (10/8/12)
  Posted 10/8/12 at 6:22pm via finsmes.com
• 
  Gliknik received $3.5M in Venture Round funding. (1/6/11)
  Posted 1/6/11 at 6:15pm via finsmes.com
• 
  Gliknik added David S. Block as President and CEO.
  Posted 1/6/11 at 6:15pm

Videos

Screenshots

edit

Sources

1. Gliknik Raises $3.5M in Equity Financing (finsmes.com) [edit]
2. Gliknik Raises $4.9M in Series B Funding (finsmes.com) [edit]
3. Gliknik Increases Funding to $20M, Preps Autoimmune Disease Drug for Trials (pevc.dowjones.com) [edit]